1. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes Arch Ophthalmol. 2005;123(7):903-912. doi:10.1001/archopht.123.7.903 Standardized fluorescein angiography grading form used for this study. For all criteria, 0 indicates none; 1, mild; 2, moderate; and 3, severe. For media opacity, 0 indicates clear view of retinal capillaries; 1, dull view of vessels, but capillaries are appreciated; 2, unable to see retinal capillaries; and 3, unable to see secondary retinal vessels. For cystoid macular edema (CME; late angiographic phases), 0 indicates no perifoveal hyperfluorescence; 1, incomplete ring of leakage; 2, circumferential leakage; and 3, circumferential and broad leakage greater than the disc area. For disc hyperfluorescence (late angiographic phases), 0 indicates normal exit of fluorescein and normal staining of the scleral rim; 1, staining of the optic disc; 2, leakage at the optic disc; and 3, leakage with blurring of papillary vasculature. For retinal vascular hyperfluorescence (late angiographic phases), 0 indicates normal exit of fluorescein; 1, staining of vessels; 2, leakage; and 3, more leakage. For diffuse leakage, 0 indicates none; 1, small or isolated foci of leakage; 2, moderate; and 3, numerous or large areas of leakage. For choroidal filling defect, 0 indicates none; 1, small areas; 2, moderate; and 3, larger areas. Figure Legend:

2. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes Arch Ophthalmol. 2005;123(7):903-912. doi:10.1001/archopht.123.7.903 Visual acuity before and after infliximab therapy at 10 weeks. Logarithm of the minimum angle of resolution (logMAR) equivalents was calculated from visual acuity recorded on standard clinic Snellen charts as follows: 20/15 indicates −0.1; 20/20, 0.0; 20/30, 0.2; 20/40, 0.3; 20/50, 0.4; 20/60, 0.5; 20/70, 0.55; 20/80, 0.6; 20/100, 0.7; 20/150, 0.85; 20/200, 1.0; and 20/400, 2.0. All visual acuity measurements worse than 20/400 (ie, counting fingers, hand motions, light perception, and no light perception) were arbitrarily classified as 2.5. Each eye of treated patients is plotted singly; however, points on the scatterplot may represent multiple eyes of patients or patients with identical pretreatment and posttreatment acuities. Figure Legend:

3. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes Arch Ophthalmol. 2005;123(7):903-912. doi:10.1001/archopht.123.7.903 Patient self-assessment of their quality of vision. A, Visual analog scale used at each visit to measure patient perception of visual function. B, Scatterplot demonstrating the patient’s perception of visual function using the visual analog scale (graded on a continuous scale of 0-10 on the scale illustrated in part A) at weeks 0, 10, and 50 in the study. Figure Legend:

4. Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: A Prospective Trial of Infliximab Therapy for Refractory Uveitis: Preliminary Safety and Efficacy Outcomes Arch Ophthalmol. 2005;123(7):903-912. doi:10.1001/archopht.123.7.903 Sequential fundus photographs in patient 7. A and B, Neovascularization of the optic discs (arrows) bilaterally and vitreous haze before starting infliximab therapy. C and D, Resolution of vitreous haze 10 weeks after infliximab therapy. Arrows denote persistent neovascularization. E and F, Two years after treatment. Notable regression of neovascularization has occurred. Figure Legend: